[Thymopentin as adjuvant therapy in the hepatitis B vaccination of non- or hyporesponsive subjects].
The efficacy of thymopentin as adjuvant therapy was assessed in 13 people who did not respond to standard anti-hepatitis B vaccination with Pasteur HEVAC or Merck HV-VAX. Thymopentin (Sindtomodulina, Italfarmaco)--was given in doses of 50 mg 3 times a week for 3 consecutive weeks, a booster dose of the vaccine (40 mcg HB VAX injected into the deltoid muscle, or 10 mcg HEVAC subcutaneous) being given at the start of the second week. In 69.23% of the patients whose anamnesis revealed no immune deficiency, the Merrieux Multitest showed defective cell-mediated immunity. The adjuvant treatment produced an adequate immune response to the vaccine (anti ABc antibody titre 10 mU/ml) in 76.9% of cases and normalised cell-mediated immunity in 66.6% of those found to be hypoanergic at basal screening.
Istituto Piccolo Cottolengo di Don Orione, Genova.
P
P
Fuliano
L
L
Fontana
M
M
Bigolari
U
U
Bovone
G
G
Orengo
F
F
Astengo
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D005260:Female; D006509:Hepatitis B / Q000276:immunology / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000032:analysis; D006801:Humans; D007117:Immunization, Secondary; D008297:Male; D008875:Middle Aged; D010446:Peptide Fragments / Q000627:therapeutic use*; D012307:Risk Factors; D016305:Thymopentin; D013946:Thymopoietins / Q000627:therapeutic use*; D013951:Thymus Hormones / Q000627:therapeutic use*; D013997:Time Factors; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000276:immunology*
D000276:Adjuvants, Immunologic; D006510:Hepatitis B Antibodies; D010446:Peptide Fragments; D013946:Thymopoietins; D013951:Thymus Hormones; D014761:Viral Hepatitis Vaccines; D016305:Thymopentin
La timopentina come terapia adiuvante nella vaccinazione anti-epatite B in soggetti non-O iporesponsivi.